论文部分内容阅读
目的探讨免疫印迹技术对幽门螺杆菌(Hp)的检测及分型诊断的应用价值。方法应用免疫印迹技术检测61例确诊的上消化道疾病(包括慢性胃炎、消化性溃疡、胃癌)患者和20例无症状健康志愿者血清中的幽门螺杆菌空泡毒素(VacA)、细胞毒素(CagA)和尿素酶(Ureas)等Hp抗体,并分为Ⅰ型和Ⅱ型。结合14C呼气试验和胃镜检查分析。结果慢性胃炎组、消化性溃疡组、胃癌组的HpⅠ型阳性率分别为66.6%、89.5%、100%,与对照组(25%)的差别有统计学意义(P<0.05和P<0.01)。慢性胃炎组、消化性溃疡组、胃癌组的HPⅡ型阳性率分别为20%、2.6%、0%,消化性溃疡组、胃癌组HPⅡ型阳性率与对照组的差别有统计学意义。并且发现随病变由良性到恶性,CagA/VacA的表达呈上升的趋势,尤其是VacA的表达,在慢性胃炎组、消化性溃疡组、胃癌组的阳性率分别为53.3%、81.6%、100%。结论免疫印迹技术可应用于对Hp感染分型诊断,为临床治疗及判断预后提供一定依据。
Objective To investigate the value of immunoblotting in the detection and classification of Helicobacter pylori (Hp). Methods Western blotting was used to detect Helicobacter pylori vacuolar detoxification (VacA), cytotoxin (CIN) in 61 patients with diagnosed upper gastrointestinal diseases (including chronic gastritis, peptic ulcer, gastric cancer) and 20 asymptomatic healthy volunteers. CagA) and urease (Ureas) and other Hp antibodies, and is divided into type Ⅰ and type Ⅱ. Combined 14C breath test and gastroscopy analysis. Results The positive rates of HpⅠtype in chronic gastritis group, peptic ulcer group and gastric cancer group were 66.6%, 89.5%, 100%, respectively, which were significantly different from those in control group (25%) (P <0.05 and P <0.01) . The positive rates of HP Ⅱ in chronic gastritis group, peptic ulcer group and gastric cancer group were 20%, 2.6% and 0% respectively. The positive rates of HP Ⅱ in peptic ulcer group and gastric cancer group were statistically different from those in control group. The positive rates of CagA / VacA, especially VacA, were found to be 53.3%, 81.6%, 100% respectively in chronic gastritis, peptic ulcer and gastric cancer as the pathological changes from benign to malignant. . Conclusion Western blotting can be applied to the diagnosis of Hp infection and provide some evidences for clinical treatment and prognosis.